41 results on '"Altucci L"'
Search Results
2. Tumour cell population growth inhibition and cell death induction of functionalized 6-aminoquinolone derivatives
- Author
-
Franci, G., Manfroni, G., Cannalire, R., Felicetti, T., Tabarrini, O., Salvato, A., Barreca, M. L., Altucci, L., and Cecchetti, V.
- Published
- 2015
- Full Text
- View/download PDF
3. Effect of bisphenol A with or without enzyme treatment on the proliferation and viability of MCF-7 cells
- Author
-
Ricupito, A., Del Pozzo, G., Diano, N., Grano, V., Portaccio, M., Marino, M., Bolli, A., Galluzzo, P., Bontempo, P., Mita, L., Altucci, L., and Mita, D.G.
- Published
- 2009
- Full Text
- View/download PDF
4. UHRF1 coordinates peroxisome proliferator activated receptor gamma (PPARG) epigenetic silencing and mediates colorectal cancer progression
- Author
-
Sabatino, L, Fucci, A, Pancione, M, Carafa, V, Nebbioso, A, Pistore, C, Babbio, F, Votino, C, Laudanna, C, Ceccarelli, M, Altucci, L, Bonapace, I M, and Colantuoni, V
- Published
- 2012
- Full Text
- View/download PDF
5. Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1
- Author
-
Chaib, H, Nebbioso, A, Prebet, T, Castellano, R, Garbit, S, Restouin, A, Vey, N, Altucci, L, and Collette, Y
- Published
- 2012
- Full Text
- View/download PDF
6. Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation
- Author
-
Borbone, E, Berlingieri, M T, De Bellis, F, Nebbioso, A, Chiappetta, G, Mai, A, Altucci, L, and Fusco, A
- Published
- 2010
- Full Text
- View/download PDF
7. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect
- Author
-
Lara, E, Mai, A, Calvanese, V, Altucci, L, Lopez-Nieva, P, Martinez-Chantar, M L, Varela-Rey, M, Rotili, D, Nebbioso, A, Ropero, S, Montoya, G, Oyarzabal, J, Velasco, S, Serrano, M, Witt, M, Villar-Garea, A, Inhof, A, Mato, J M, Esteller, M, and Fraga, M F
- Published
- 2009
- Full Text
- View/download PDF
8. Genista sessilifolia DC. extracts induce apoptosis across a range of cancer cell lines
- Author
-
Bontempo, P., Rigano, D., Doto, A., Formisano, C., Conte, M., Nebbioso, A., Carafa, V., Caserta, G., Sica, V., Molinari, A. M., and Altucci, L.
- Published
- 2013
- Full Text
- View/download PDF
9. The new low-toxic histone deacetylase inhibitor S-(2) induces apoptosis in various acute myeloid leukaemia cells
- Author
-
Cellai, C., Balliu, M., Laurenzana, A., Guandalini, L., Matucci, R., Miniati, D., Torre, E., Nebbioso, A., Carafa, V., Altucci, L., Romanelli, M. N., and Paoletti, F.
- Published
- 2012
- Full Text
- View/download PDF
10. Psidium guajava L. anti-neoplastic effects: induction of apoptosis and cell differentiation
- Author
-
Bontempo, P., Doto, A., Miceli, M., Mita, L., Benedetti, R., Nebbioso, A., Veglione, M., Rigano, D., Cioffi, M., Sica, V., Molinari, A. M., and Altucci, L.
- Published
- 2012
- Full Text
- View/download PDF
11. Retinoic-acid-induced apoptosis in leukemia cells
- Author
-
Jiménez-Lara, A.M., Clarke, N., Altucci, L., and Gronemeyer, H.
- Published
- 2004
- Full Text
- View/download PDF
12. Age-related miRNome landscape of cumulus oophorus cells during controlled ovarian stimulation protocols in IVF cycles.
- Author
-
Dell'Aversana, C, Cuomo, F, Longobardi, S, D'Hooghe, T, Caprio, F, Franci, G, Santonastaso, M, Colacurci, N, Barone, S, Pisaturo, V, Valerio, D, and Altucci, L
- Subjects
CUMULUS cells (Embryology) ,EMBRYOS ,INDUCED ovulation ,OVARIAN function tests ,OVUM donation ,MITOGEN-activated protein kinases ,RNA polymerases ,REPRODUCTIVE technology ,RESEARCH ,OVUM ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,CELLS ,FERTILIZATION in vitro - Abstract
Study Question: Is the microRNA (miRNA) expression pattern of cumulus oophorus cells (COCs) in women undergoing medically assisted reproduction (MAR) procedures differentially modulated according to patient age and gonadotropin treatment strategy?Summary Answer: Maternal age is an independent factor impacting miRNA expression in COCs while gonadotropin treatment may affect follicular miRNA expression and IVF efficacy.What Is Known Already: Epigenetic mechanisms in female infertility are complex and poorly studied. DNA methylation, histone modifications, miRNAs and nucleosome positioning influence cellular machinery through positive and negative feedback mechanisms either alone or interactively. miRNAs are important regulators during oogenesis, spermatogenesis and early embryogenesis, and are reported to play a role in regulating crosstalk between the oocyte and COCs. Although miRNome analysis has been performed in female human reproductive tissues (endometrium, myometrium, cervix and ovaries), epigenetic modifications in women with infertility have not been explored in detail. In addition, the impact of gonadotropin treatments during MAR on miRNA expression in COCs has not been fully investigated.Study Design, Size, Duration: This study was carried out in 53 COC samples obtained from mature metaphase II (MII) oocytes in 53 women undergoing MAR treatment. A total of 38 samples for assay development were pooled by maternal age and gonadotropin treatment into four predetermined subgroups: ≥36 years and recombinant human FSH (r-hFSH), n = 10; ≥36 years and r-hFSH+ recombinant human-luteinizing hormone (r-hLH), n = 10; ≤35 years and r-hFSH, n = 9; ≤35 years and r-hFSH+r-hLH, n = 9. miRNome profiles were determined and compared between subgroups. Expression of defined miRNAs was validated in the remaining fifteen samples, representative of each subgroup, by quantitative polymerase chain reaction (PCR).Participants/materials, Setting, Methods: COCs were processed for miRNA-enriched total RNA extraction and pooled in homogeneous subgroups to obtain a sufficient amount and quality of starting material to perform the analysis. Each pooled sample underwent miRNA profiling using PCR assay system to examine expression of 752 human miRNAs without pre-amplification. Data were analyzed using the delta-delta Ct method for relative quantitation and prediction of target genes (with at least four algorithms predicting the same miRNA-gene interaction pair (HIT)>4). The miRSystem database provided functional annotation enrichment (raw P-value <0.05) of co-expressed miRNAs.Main Results and the Role Of Chance: We found distinctive miRNA expression profiles in each subgroup correlating with age and MAR stimulation. In addition, a number of selective and co-expressed miRNAs were revealed by comparative analysis. A cluster of 37 miRNAs were commonly but differentially expressed in all four pools. Significant differences were observed in expression regulation of 37 miRNAs between age groups (≤35 or ≥36) in women receiving r-hFSH+r-hLH compared to those receiving r-hFSH alone. Higher concentrations and increased numbers of miRNAs were recorded in younger than in older patients, regardless of treatment. Functional and expression studies performed to retrieve common miRNome profiles revealed an enrichment of biological functions in oocyte growth and maturation, embryo development, steroidogenesis, ovarian hyperstimulation, apoptosis and cell survival, glucagon and lipid metabolism, and cell trafficking. The highest scored pathways of target genes of the 37 common miRNAs were associated with mitogen-activated protein kinase (MAPK) signaling pathways, G alpha signaling, transcription regulation, tight junctions, RNA polymerase I and III, and mitochondrial transcription. We identified a potential age- and MAR stimulation-dependent signature in the miRNA landscape of COCs.Limitations, Reasons For Caution: We cannot rule out the possibility that other unknown individual genetic or clinical factors may have interfered with the reported results. Since miRNA profiling was conducted with a predefined array of target probes, other miRNA molecules, potentially modulated by age and hormonal stimulation, may have been missed in this study.Wider Implications Of the Findings: miRNA expression in COCs is modulated by gonadotropin treatment and correlates strongly with age. A better understanding of the expression patterns and functions of miRNAs may lead to the development of novel therapeutics to treat ovarian dysfunction and improve fertility in older women.Study Funding/competing Interest: This study was funded by Merck KGaA, Darmstadt, Germany. All authors declared no competing interest, except SL and TD who are fully employed by Merck KGaA.Trial Registration Number: N/A. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
13. Different Approaches to Unveil Biomolecule Configurations and Their Mutual Interactions.
- Author
-
Benedetti, R., Bajardi, F., Capozziello, S., Carafa, V., Conte, M., Del Sorbo, M. R., Nebbioso, A., Singh, M., Stunnenberg, H. G., Valadan, M., Altucci, L., and Altucci, C.
- Subjects
MOLECULAR shapes ,ULTRASHORT laser pulses ,BIOMOLECULES ,NUCLEIC acids ,RAS oncogenes ,ESTROGEN receptors - Abstract
A novel technique was demonstrated that overcomes important drawbacks to crosslink cells by irradiation with ultrashort ultraviolet laser pulses (L-crosslinking). To use this technique coupled to Chromatin ImmunoPrecipitation (ChIP) in a high throughput context, a prescreening fast method needs to be implemented to set up suitable irradiation conditions of the cell sample for efficient L-crosslinking with no final and long ChIP analysis. Here a fast method is reported where living human cells have been first transfected with a vector coding for Estrogen Receptor α (ERα), linked to Green Florescent protein (ERα-GFP), so that the well-known interaction between the Estrogen Receptor Elements (ERE) region of the cell DNA and the ERα protein can be detected by studying the fluorometric response of the irradiated cells. The damage induced to cells by ultraviolet irradiation is characterized by looking at the DNA integrity, protein stability, and cellular viability. A second novel approach is presented to analyze or re-visit DNA and RNA sequences and their molecular configurations. This approach is based on methods derived from Chern-Simons super-gravity adapted to describe mutations in DNA/RNA strings, as well as interactions between nucleic acids. As a preliminary case, we analyze the KRAS human gene sequence and some of its mutations. Interestingly, our model shows how the Chern-Simons currents are able to characterize the mutations within a sequence, in particular giving a quantitative indication of the mutation likelihood. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Synthesis of 7-alkylidene-7,12-dihydroindolo[3,2-d]benzazepine-6-(5H)-ones (7-alkylidene-paullones) by N-cyclization–oxidative Heck cascade and characterization as sirtuin modulators.
- Author
-
Denis, J. G., Franci, G., Altucci, L., Aurrecoechea, J. M., de Lera, Á. R., and Álvarez, R.
- Published
- 2015
- Full Text
- View/download PDF
15. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015.
- Author
-
Galluzzi, L, Bravo-San Pedro, J M, Vitale, I, Aaronson, S A, Abrams, J M, Adam, D, Alnemri, E S, Altucci, L, Andrews, D, Annicchiarico-Petruzzelli, M, Baehrecke, E H, Bazan, N G, Bertrand, M J, Bianchi, K, Blagosklonny, M V, Blomgren, K, Borner, C, Bredesen, D E, Brenner, C, and Campanella, M
- Subjects
CELL death inhibition ,CELL-mediated cytotoxicity ,GENETIC code ,GENETIC transcription ,GENETIC engineering research - Abstract
Cells exposed to extreme physicochemical or mechanical stimuli die in an uncontrollable manner, as a result of their immediate structural breakdown. Such an unavoidable variant of cellular demise is generally referred to as 'accidental cell death' (ACD). In most settings, however, cell death is initiated by a genetically encoded apparatus, correlating with the fact that its course can be altered by pharmacologic or genetic interventions. 'Regulated cell death' (RCD) can occur as part of physiologic programs or can be activated once adaptive responses to perturbations of the extracellular or intracellular microenvironment fail. The biochemical phenomena that accompany RCD may be harnessed to classify it into a few subtypes, which often (but not always) exhibit stereotyped morphologic features. Nonetheless, efficiently inhibiting the processes that are commonly thought to cause RCD, such as the activation of executioner caspases in the course of apoptosis, does not exert true cytoprotective effects in the mammalian system, but simply alters the kinetics of cellular demise as it shifts its morphologic and biochemical correlates. Conversely, bona fide cytoprotection can be achieved by inhibiting the transduction of lethal signals in the early phases of the process, when adaptive responses are still operational. Thus, the mechanisms that truly execute RCD may be less understood, less inhibitable and perhaps more homogeneous than previously thought. Here, the Nomenclature Committee on Cell Death formulates a set of recommendations to help scientists and researchers to discriminate between essential and accessory aspects of cell death. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
16. Nonlinear protein - nucleic acid crosslinking induced by femtosecond UV laser pulses in living cells.
- Author
-
Altucci, C., Nebbioso, A., Benedetti, R., Esposito, R., Carafa, V., Conte, M., Micciarelli, M., Altucci, L., and Velotta, R.
- Published
- 2012
- Full Text
- View/download PDF
17. The Helicobacter pylori's protein VacA has direct effects on the regulation of cell cycle and apoptosis in gastric epithelial cells.
- Author
-
Manente, L., Perna, A., Buommino, E., Altucci, L., Lucariello, A., Citro, G., Baldi, A., Iaquinto, G., Tufano, M. A., and De Luca, A.
- Subjects
HELICOBACTER pylori ,CELL cycle ,APOPTOSIS ,EPITHELIAL cells ,PROTEINS ,CELL death - Abstract
In this study, we have evaluated the effects on cell cycle regulation of VacA alone and in combination with other two Helicobacter pylori proteins, cytotoxin-associated protein (CagA) and HspB, using the human gastric epithelial cells (AGS). Our results indicate that VacA alone was able to inhibit the G1 to S progression of the cell cycle. The VacA capacity of inhibiting cell progression from G1 to S phase was also observed when cells were co-transfected with CagA or HspB. Moreover, VacA over-expression caused apoptosis in AGS cells through activation of caspase 8 and even more of caspase 9, thus indicating an involvement of both the receptor-mediated and the mitochondrial pathways of apoptosis. Indeed, the two pathways probably can co-operate to execute cell death with a prevalence of the mitochondrial pathways. Our data taken together provide additional information to further enhance our understanding of the molecular mechanism by which H. pylori proteins alter the growth status of human gastric epithelial cells. J. Cell. Physiol. 214: 582–587, 2008. © 2007 Wiley-Liss, Inc. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
18. Epigenome-based treatment against cancer.
- Author
-
Carafa, V. and Altucci, L.
- Subjects
- *
CANCER treatment , *EPIGENOMICS , *APOPTOSIS - Published
- 2019
- Full Text
- View/download PDF
19. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015
- Author
-
Galluzzi, L, Bravo-San Pedro, J M, Vitale, I, Aaronson, S A, Abrams, J M, Adam, D, Alnemri, E S, Altucci, L, Andrews, D, Annicchiarico-Petruzzelli, M, Baehrecke, E H, Bazan, N G, Bertrand, M J, Bianchi, K, Blagosklonny, M V, Blomgren, K, Borner, C, Bredesen, D E, Brenner, C, Campanella, M, Candi, E, Cecconi, F, Chan, F K, Chandel, N S, Cheng, E H, Chipuk, J E, Cidlowski, J A, Ciechanover, A, Dawson, T M, Dawson, V L, De Laurenzi, V, De Maria, R, Debatin, K-M, Di Daniele, N, Dixit, V M, Dynlacht, B D, El-Deiry, W S, Fimia, G M, Flavell, R A, Fulda, S, Garrido, C, Gougeon, M-L, Green, D R, Gronemeyer, H, Hajnoczky, G, Hardwick, J M, Hengartner, M O, Ichijo, H, Joseph, B, Jost, P J, Kaufmann, T, Kepp, O, Klionsky, D J, Knight, R A, Kumar, S, Lemasters, J J, Levine, B, Linkermann, A, Lipton, S A, Lockshin, R A, López-Otín, C, Lugli, E, Madeo, F, Malorni, W, Marine, J-C, Martin, S J, Martinou, J-C, Medema, J P, Meier, P, Melino, S, Mizushima, N, Moll, U, Muñoz-Pinedo, C, Nuñez, G, Oberst, A, Panaretakis, T, Penninger, J M, Peter, M E, Piacentini, M, Pinton, P, Prehn, J H, Puthalakath, H, Rabinovich, G A, Ravichandran, K S, Rizzuto, R, Rodrigues, C M, Rubinsztein, D C, Rudel, T, Shi, Y, Simon, H-U, Stockwell, B R, Szabadkai, G, Tait, S W, Tang, H L, Tavernarakis, N, Tsujimoto, Y, Vanden Berghe, T, Vandenabeele, P, Villunger, A, Wagner, E F, Walczak, H, White, E, Wood, W G, Yuan, J, Zakeri, Z, Zhivotovsky, B, Melino, G, and Kroemer, G
- Abstract
Cells exposed to extreme physicochemical or mechanical stimuli die in an uncontrollable manner, as a result of their immediate structural breakdown. Such an unavoidable variant of cellular demise is generally referred to as ‘accidental cell death' (ACD). In most settings, however, cell death is initiated by a genetically encoded apparatus, correlating with the fact that its course can be altered by pharmacologic or genetic interventions. ‘Regulated cell death' (RCD) can occur as part of physiologic programs or can be activated once adaptive responses to perturbations of the extracellular or intracellular microenvironment fail. The biochemical phenomena that accompany RCD may be harnessed to classify it into a few subtypes, which often (but not always) exhibit stereotyped morphologic features. Nonetheless, efficiently inhibiting the processes that are commonly thought to cause RCD, such as the activation of executioner caspases in the course of apoptosis, does not exert true cytoprotective effects in the mammalian system, but simply alters the kinetics of cellular demise as it shifts its morphologic and biochemical correlates. Conversely, bona fide cytoprotection can be achieved by inhibiting the transduction of lethal signals in the early phases of the process, when adaptive responses are still operational. Thus, the mechanisms that truly execute RCD may be less understood, less inhibitable and perhaps more homogeneous than previously thought. Here, the Nomenclature Committee on Cell Death formulates a set of recommendations to help scientists and researchers to discriminate between essential and accessory aspects of cell death.
- Published
- 2014
- Full Text
- View/download PDF
20. The Jumonji family: past, present and future of histone demethylases in cancer
- Author
-
Franci Gianluigi, Ciotta Alfonso, and Altucci Lucia
- Subjects
cancer ,chromatin-modulating drugs ,epigenetics ,histone demethylases ,jumonji family. ,Biology (General) ,QH301-705.5 - Abstract
The first Jumonji gene was cloned in 1995 by Takeuchi et al. [Takeuchi T, Yamazaki Y, Katoh-Fukui Y, Tsuchiya R, Kondo S, Motoyama J, Higashinakagawa T. Gene trap capture of a novel mouse gene, jumonji, required for neural tube formation. Genes Dev 1995; 9: 1211–22.]. Several genes sharing similar biological features have since been discovered, and are currently grouped into the JMJ family. Interestingly, their deregulation has been associated with cardiac disease, obesity, neurological disorders and cancer. One of the mechanisms underlying their function is gene expression modulation via histone post-translational modifications (PTMs). Increasing evidence of Jumonji deregulation in tumours such as colon, prostate, haematological and breast cancer is continually emerging, hence the need to acquire a better understanding. The Genesapiens.org database of patient arrays allows target expression levels to be investigated in a wide range of cancers, corroborating and extending the role of the JMJ family. Here, we provide an overview of the expression profile and regulation of JMJ family members in cancer, examining the most recent literature in the light of analyses drawn from this database.
- Published
- 2014
- Full Text
- View/download PDF
21. Comment on: LncRNA SBF2-AS1 promotes hepatocellular carcinoma metastasis by regulating EMT and predicts unfavorable prognosis.
- Author
-
Franci, G., Dell'Aversana, C., Stelitano, D., Rinaldi, M., and Altucci, L.
- Published
- 2019
- Full Text
- View/download PDF
22. A genic and epigenetic combination therapy for liver cancer.
- Author
-
Rinaldi, L., Franci, G., Folliero, V., Palomba, L., Isticato, R., Zannella, C., di Francia, R., De Sio, I., Morelli, G., S.Lastoria, null, Altucci, L., Pedone, C., Ascione, A., Adinolfi, L.E., and Galdiero, M.
- Published
- 2017
- Full Text
- View/download PDF
23. 266 UVI5008, a novel epigenetic enzyme inhibitor.
- Author
-
Khanwalkar, H., De Lera, A.R., Altucci, L., Stunnenberg, H., and Gronemeyer, H.
- Published
- 2010
- Full Text
- View/download PDF
24. ChemInform Abstract: Synthesis of 7-Alkylidene-7,12-dihydroindolo[3,2-d]benzazepine-6-(5H)-ones (7-Alkylidene-paullones) by N-Cyclization-Oxidative Heck Cascade and Characterization as Sirtuin Modulators.
- Author
-
Denis, J. G., Franci, G., Altucci, L., Aurrecoechea, J. M., de Lera, A. R., and Alvarez, R.
- Published
- 2015
- Full Text
- View/download PDF
25. 'Shock and kill' effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence
- Author
-
Altucci Lucia, Rotili Dante, Valente Sergio, El Daker Sary, Norelli Sandro, Mai Antonello, Savarino Andrea, Palamara Anna, and Garaci Enrico
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Abstract
Abstract Latently infected, resting memory CD4+ T cells and macrophages represent a major obstacle to the eradication of HIV-1. For this purpose, "shock and kill" strategies have been proposed (activation of HIV-1 followed by stimuli leading to cell death). Histone deacetylase inhibitors (HDACIs) induce HIV-1 activation from quiescence, yet class/isoform-selective HDACIs are needed to specifically target HIV-1 latency. We tested 32 small molecule HDACIs for their ability to induce HIV-1 activation in the ACH-2 and U1 cell line models. In general, potent activators of HIV-1 replication were found among non-class selective and class I-selective HDACIs. However, class I selectivity did not reduce the toxicity of most of the molecules for uninfected cells, which is a major concern for possible HDACI-based therapies. To overcome this problem, complementary strategies using lower HDACI concentrations have been explored. We added to class I HDACIs the glutathione-synthesis inhibitor buthionine sulfoximine (BSO), in an attempt to create an intracellular environment that would facilitate HIV-1 activation. The basis for this strategy was that HIV-1 replication decreases the intracellular levels of reduced glutathione, creating a pro-oxidant environment which in turn stimulates HIV-1 transcription. We found that BSO increased the ability of class I HDACIs to activate HIV-1. This interaction allowed the use of both types of drugs at concentrations that were non-toxic for uninfected cells, whereas the infected cell cultures succumbed more readily to the drug combination. These effects were associated with BSO-induced recruitment of HDACI-insensitive cells into the responding cell population, as shown in Jurkat cell models for HIV-1 quiescence. The results of the present study may contribute to the future design of class I HDACIs for treating HIV-1. Moreover, the combined effects of class I-selective HDACIs and the glutathione synthesis inhibitor BSO suggest the existence of an Achilles' heel that could be manipulated in order to facilitate the "kill" phase of experimental HIV-1 eradication strategies.
- Published
- 2009
- Full Text
- View/download PDF
26. Molecular analysis of the apoptotic effects of BPA in acute myeloid leukemia cells
- Author
-
Del Pozzo Giovanna, Bolli Alessandro, Marino Maria, D'Amato Loredana, Benedetti Rosaria, Di Cerbo Vincenzo, Manzo Fabio, De Bellis Floriana, Conte Mariarosaria, Carafa Vincenzo, Menafra Roberta, Franci GianLuigi, Lepore Ilaria, Nebbioso Angela, Miceli Marco, Doto Antonella, Mita Luigi, Bontempo Paola, Diano Nadia, Portaccio Marianna, Mita Gustavo D, Vietri Maria, Cioffi Michele, Nola Ernesto, Dell'Aversana Carmela, Sica Vincenzo, Molinari Anna, and Altucci Lucia
- Subjects
Medicine - Abstract
Abstract Background: BPA (bisphenol A or 2,2-bis(4-hydroxy-phenol)propane) is present in the manufacture of polycarbonate plastic and epoxy resins, which can be used in impact-resistant safety equipment and baby bottles, as protective coatings inside metal food containers, and as composites and sealants in dentistry. Recently, attention has focused on the estrogen-like and carcinogenic adverse effects of BPA. Thus, it is necessary to investigate the cytotoxicity and apoptosis-inducing activity of this compound. Methods: Cell cycle, apoptosis and differentiation analyses; western blots. Results: BPA is able to induce cell cycle arrest and apoptosis in three different acute myeloid leukemias. Although some granulocytic differentiation concomitantly occurred in NB4 cells upon BPA treatment, the major action was the induction of apoptosis. BPA mediated apoptosis was caspase dependent and occurred by activation of extrinsic and intrinsic cell death pathways modulating both FAS and TRAIL and by inducing BAD phosphorylation in NB4 cells. Finally, also non genomic actions such as the early decrease of both ERK and AKT phosphorylation were induced by BPA thus indicating that a complex intersection of regulations occur for the apoptotic action of BPA. Conclusion: BPA is able to induce apoptosis in leukemia cells via caspase activation and involvement of both intrinsic and extrinsic pathways of apoptosis.
- Published
- 2009
- Full Text
- View/download PDF
27. Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability
- Author
-
Sacchi Ada, Altucci Lucia, Menegozzo Simona, Galati Rossella, Nebbioso Angela, Cardillo Irene, Verdina Alessandra, and Baldi Alfonso
- Subjects
Medicine - Abstract
Abstract Nonsteroidal anti-inflammatory drugs (NSAIDs) have been proposed for prevention and treatment of a variety of human cancers. Piroxicam, in particular, has been recently shown to exert significant anti-tumoral activity in combination with cisplatin (CDDP) on mesothelioma cells. However, the mechanisms through which NSAIDs regulate the cell cycle as well as the signal pathways involved in the growth inhibition, remain unclear. In the present study, using two mesothelioma cell lines, MSTO-211H and NCI-H2452, we have investigated the influence of piroxicam alone and in association with CDDP on proliferation, cell cycle regulation and apoptosis. In both cell lines a significant effect on cell growth inhibition, respect to the control, was observed with all the drugs tested. Moreover, treatment with piroxicam or CDDP alone altered the cell cycle phase distribution as well as the expression of some cell cycle regulatory proteins in both cell lines. These effects were increased, even if in a not completely overlapping manner, after treatment with the association of piroxicam and CDDP. In particular, the two drugs in NCI cell line had a synergistic effect on apoptosis, probably through activation of caspase 8 and caspase 9, while the most evident targets among the cell cycle regulators were cyclin D1 and p21waf1. These results suggest that the association of piroxicam and CDDP specifically triggers cell cycle regulation and apoptosis in different mesothelioma cell lines and may hold promise in the treatment of mesothelioma.
- Published
- 2008
- Full Text
- View/download PDF
28. Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability.
- Author
-
Verdina A, Cardillo I, Nebbioso A, Galati R, Menegozzo S, Altucci L, Sacchi A, Baldi A, Verdina, Alessandra, Cardillo, Irene, Nebbioso, Angela, Galati, Rossella, Menegozzo, Simona, Altucci, Lucia, Sacchi, Ada, and Baldi, Alfonso
- Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) have been proposed for prevention and treatment of a variety of human cancers. Piroxicam, in particular, has been recently shown to exert significant anti-tumoral activity in combination with cisplatin (CDDP) on mesothelioma cells. However, the mechanisms through which NSAIDs regulate the cell cycle as well as the signal pathways involved in the growth inhibition, remain unclear. In the present study, using two mesothelioma cell lines, MSTO-211H and NCI-H2452, we have investigated the influence of piroxicam alone and in association with CDDP on proliferation, cell cycle regulation and apoptosis. In both cell lines a significant effect on cell growth inhibition, respect to the control, was observed with all the drugs tested. Moreover, treatment with piroxicam or CDDP alone altered the cell cycle phase distribution as well as the expression of some cell cycle regulatory proteins in both cell lines. These effects were increased, even if in a not completely overlapping manner, after treatment with the association of piroxicam and CDDP. In particular, the two drugs in NCI cell line had a synergistic effect on apoptosis, probably through activation of caspase 8 and caspase 9, while the most evident targets among the cell cycle regulators were cyclin D1 and p21waf1. These results suggest that the association of piroxicam and CDDP specifically triggers cell cycle regulation and apoptosis in different mesothelioma cell lines and may hold promise in the treatment of mesothelioma. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
29. Stimulation of Human Breast Cancer MCF-7 Cells with Estrogen Prevents Cell Cycle Arrest by HMG-CoA Reductase Inhibitors
- Author
-
Addeo, R., Altucci, L., Battista, T., Bonapace, I.M., Cancemi, M., Cicatiello, L., Germano, D., Pacilio, C., Salzano, S., Bresciani, F., and Weisz, A.
- Published
- 1996
- Full Text
- View/download PDF
30. Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer’s Disease
- Author
-
Deborah Pietrobono, Nicola Petragnani, Vincenza Andrisano, Claudia Martini, Vincenzo Tumiatti, Nibal Betari, Serena Montanari, Simona Daniele, Lara Davani, Angela Nebbioso, Ettore Novellino, F. Frabetti, Barbara Monti, Pasquale Russomanno, Angela De Simone, Andrea Milelli, Federica Sarno, Lucia Altucci, Patrizia Ballerini, Raffaella Casadei, Valeria La Pietra, Mariarosaria Conte, Sabrina Petralla, De Simone, Angela, La Pietra, Valeria, Betari, Nibal, Petragnani, Nicola, Conte, Mariarosaria, Daniele, Simona, Pietrobono, Deborah, Martini, Claudia, Petralla, Sabrina, Casadei, Raffaella, Davani, Lara, Frabetti, Flavia, Russomanno, Pasquale, Novellino, Ettore, Montanari, Serena, Tumiatti, Vincenzo, Ballerini, Patrizia, Sarno, Federica, Nebbioso, Angela, Altucci, Lucia, Monti, Barbara, Andrisano, Vincenza, Milelli, Andrea, De Simone A, La Pietra V, Betari N, Petragnani N, Conte M, Daniele S, Pietrobono D, Martini C, Petralla S, Casadei R, Davani L, Frabetti F, Russomanno P, Novellino E, Montanari S, Tumiatti V, Ballerini P, Sarno F, Nebbioso A, Altucci L, Monti B, Andrisano V, Milelli A., De Simone, A., La Pietra, V., Betari, N., Petragnani, N., Conte, M., Daniele, S., Pietrobono, D., Martini, C., Petralla, S., Casadei, R., D'Avani, Paolo, Frabetti, F., Novellino, E., Montanari, S., Tumiatti, V., Ballerini, P., Sarno, F., Nebbioso, A., Altucci, L., Monti, B., Andrisano, ANGELA-MARIA, and Milelli, A.
- Subjects
dual binding agents ,Polypharmacology, epigenetics, dual binding agents, glycogen synthase kinase 3β, histone deacetylases, neuroprotection ,Polypharmacology ,Disease ,01 natural sciences ,Biochemistry ,Neuroprotection ,GSK-3 ,Drug Discovery ,Epigenetics ,epigenetics ,glycogen synthase kinase 3β ,histone deacetylases ,neuroprotection ,biology ,010405 organic chemistry ,Chemistry ,Drug Discovery3003 Pharmaceutical Science ,Organic Chemistry ,Neurogenesis ,0104 chemical sciences ,Cell biology ,010404 medicinal & biomolecular chemistry ,Histone ,Cell culture ,Acetylation ,dual binding agent ,histone deacetylase ,biology.protein ,epigenetic - Abstract
[Image: see text] Several evidence pointed out the role of epigenetics in Alzheimer’s disease (AD) revealing strictly relationships between epigenetic and “classical” AD targets. Based on the reported connection among histone deacetylases (HDACs) and glycogen synthase kinase 3β (GSK-3β), herein we present the discovery and the biochemical characterization of the first-in-class hit compound able to exert promising anti-AD effects by modulating the targeted proteins in the low micromolar range of concentration. Compound 11 induces an increase in histone acetylation and a reduction of tau phosphorylation. It is nontoxic and protective against H(2)O(2) and 6-OHDA stimuli in SH-SY5Y and in CGN cell lines, respectively. Moreover, it promotes neurogenesis and displays immunomodulatory effects. Compound 11 shows no lethality in a wt-zebrafish model (
- Published
- 2019
- Full Text
- View/download PDF
31. SO-24 Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase 2 VELO trial.
- Author
-
Ciardiello, D., Napolitano, S., De Falco, V., Martini, G., Martinelli, E., Della Corte, C., Esposito, L., Famiglietti, V., Di Liello, A., Avallone, A., Cardone, C., De Stefano, A., Montesarchio, V., Zampino, M., Fazio, N., Del Tufo, S., Di Maio, M., De Vita, F., Altucci, L., and Marrone, F.
- Subjects
- *
PANITUMUMAB , *OVERALL survival , *COLORECTAL cancer , *METASTASIS , *SUBGROUP analysis (Experimental design) - Published
- 2023
- Full Text
- View/download PDF
32. HAT1: Landscape of Biological Function and Role in Cancer
- Author
-
Vincenza Capone, Laura Della Torre, Daniela Carannante, Mehrad Babaei, Lucia Altucci, Rosaria Benedetti, Vincenzo Carafa, Capone, V., Della Torre, L., Carannante, D., Babaei, M., Altucci, L., Benedetti, R., and Carafa, V.
- Subjects
inflammation ,cancer ,General Medicine ,HAT1 ,epigenetic ,acetylation - Abstract
Histone modifications, as key chromatin regulators, play a pivotal role in the pathogenesis of several diseases, such as cancer. Acetylation, and more specifically lysine acetylation, is a reversible epigenetic process with a fundamental role in cell life, able to target histone and non-histone proteins. This epigenetic modification regulates transcriptional processes and protein activity, stability, and localization. Several studies highlight a specific role for HAT1 in regulating molecular pathways, which are altered in several pathologies, among which is cancer. HAT1 is the first histone acetyltransferase discovered; however, to date, its biological characterization is still unclear. In this review, we summarize and update the current knowledge about the biological function of this acetyltransferase, highlighting recent advances of HAT1 in the pathogenesis of cancer.
- Published
- 2023
- Full Text
- View/download PDF
33. MRI Radiomics in Prostate Cancer: A Reliability Study
- Author
-
Fabrizio Urraro, Valerio Nardone, Alfonso Reginelli, Carlo Varelli, Antonio Angrisani, Vittorio Patanè, Luca D’Ambrosio, Pietro Roccatagliata, Gaetano Maria Russo, Luigi Gallo, Marco De Chiara, Lucia Altucci, Salvatore Cappabianca, Urraro, F., Nardone, V., Reginelli, A., Varelli, C., Angrisani, A., Patane, V., D'Ambrosio, L., Roccatagliata, P., Russo, G. M., Gallo, L., De Chiara, M., Altucci, L., and Cappabianca, S.
- Subjects
Cancer Research ,magnetic resonance imaging (MRI) ,Oncology ,radiomics ,target therapy ,radiomic ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,prostate cancer ,texture ,RC254-282 ,Original Research - Abstract
BackgroundRadiomics can provide quantitative features from medical imaging that can be correlated to clinical endpoints. The challenges relevant to robustness of radiomics features have been analyzed by many researchers, as it seems to be influenced by acquisition and reconstruction protocols, as well as by the segmentation of the region of interest (ROI). Prostate cancer (PCa) represents a difficult playground for this technique, due to discrepancies in the identification of the cancer lesion and the heterogeneity of the acquisition protocols. The aim of this study was to investigate the reliability of radiomics in PCa magnetic resonance imaging (MRI).MethodsA homogeneous cohort of patients with a PSA rise that underwent multiparametric MRI imaging of the prostate before biopsy was tested in this study. All the patients were acquired with the same MRI scanner, with a standardized protocol. The identification and the contouring of the region of interest (ROI) of an MRI suspicious cancer lesion were done by two radiologists with great experience in prostate cancer (>10 years). After the segmentation, the texture features were extracted with LIFEx. Texture features were then tested with intraclass coefficient correlation (ICC) analysis to analyze the reliability of the segmentation.ResultsForty-four consecutive patients were included in the present analysis. In 26 patients (59.1%), the prostate biopsy confirmed the presence of prostate cancer, which was scored as Gleason 6 in 6 patients (13.6%), Gleason 3 + 4 in 8 patients (18.2%), and Gleason 4 + 3 in 12 patients (27.3%). The reliability analysis conversely showed poor reliability in the majority of the MRI acquisition (61% in T2, 89% in DWI50, 44% in DWI400, and 83% in DWI1,500), with ADC acquisition only showing better reliability (poor reliability in only 33% of the texture features).ConclusionsThe low ratio of reliability in a monoinstitutional homogeneous cohort represents a significant alarm bell for the application of MRI radiomics in the field of prostate cancer. More work is needed in a clinical setting to further study the potential of MRI radiomics in prostate cancer.
- Published
- 2021
34. KDM4 Involvement in Breast Cancer and Possible Therapeutic Approaches
- Author
-
Benluvankar Varghese, Nunzio Del Gaudio, Gilda Cobellis, Lucia Altucci, Angela Nebbioso, Varghese, B., Del Gaudio, N., Cobellis, G., Altucci, L., and Nebbioso, A.
- Subjects
Cancer Research ,Methyltransferase ,epigenetics ,histone demethylation ,Cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,JMJD2 ,Methylation ,Review ,Biology ,medicine.disease ,Histone ,Histone demethylation ,Oncology ,Chromosome instability ,Cancer research ,biology.protein ,medicine ,Gene silencing ,Epigenetics ,KDM4 ,epigenetic ,RC254-282 ,KDM4 inhibitors - Abstract
Breast cancer (BC) is the second leading cause of cancer death in women, although recent scientific and technological achievements have led to significant improvements in progression-free disease and overall survival of patients. Genetic mutations and epigenetic modifications play a critical role in deregulating gene expression, leading to uncontrolled cell proliferation and cancer progression. Aberrant histone modifications are one of the most frequent epigenetic mechanisms occurring in cancer. In particular, methylation and demethylation of specific lysine residues alter gene accessibility via histone lysine methyltransferases (KMTs) and histone lysine demethylases (KDMs). The KDM family includes more than 30 members, grouped into six subfamilies and two classes based on their sequency homology and catalytic mechanisms, respectively. Specifically, the KDM4 gene family comprises six members, KDM4A-F, which are associated with oncogene activation, tumor suppressor silencing, alteration of hormone receptor downstream signaling, and chromosomal instability. Blocking the activity of KDM4 enzymes renders them “druggable” targets with therapeutic effects. Several KDM4 inhibitors have already been identified as anticancer drugs in vitro in BC cells. However, no KDM4 inhibitors have as yet entered clinical trials due to a number of issues, including structural similarities between KDM4 members and conservation of the active domain, which makes the discovery of selective inhibitors challenging. Here, we summarize our current knowledge of the molecular functions of KDM4 members in BC, describe currently available KDM4 inhibitors, and discuss their potential use in BC therapy.
- Published
- 2021
- Full Text
- View/download PDF
35. Cardioprotective effect of a moderate and prolonged exercise training involves sirtuin pathway
- Author
-
Barbara Rinaldi, Angela Nebbioso, Loredana Sodano, Maria Donniacuo, Konrad Urbanek, Lucia Altucci, Laura Gallo, Donniacuo, M, Urbanek, K, Nebbioso, A, Sodano, L, Gallo, L, Altucci, L, Rinaldi, B, and Rinaldi, B.
- Subjects
Male ,0301 basic medicine ,Time Factors ,SIRT3 ,Carbazoles ,Myocardial Infarction ,Pharmacology ,medicine.disease_cause ,030226 pharmacology & pharmacy ,General Biochemistry, Genetics and Molecular Biology ,Random Allocation ,03 medical and health sciences ,0302 clinical medicine ,Sirtuin 1 ,Physical Conditioning, Animal ,medicine ,Animals ,Sirtuins ,Myocardial infarction ,Rats, Wistar ,General Pharmacology, Toxicology and Pharmaceutics ,Cardioprotection ,Prolonged exercise ,biology ,business.industry ,General Medicine ,medicine.disease ,Rats ,Oxidative Stress ,030104 developmental biology ,Apoptosis ,Sirtuin ,biology.protein ,Immunohistochemistry ,Sedentary Behavior ,business ,Oxidative stress ,Signal Transduction - Abstract
Aim To investigate the cardioprotective effects of prolonged and moderate exercise training on cellular and molecular events early after myocardial infarction. Materials and methods Male Wistar rats were divided in sedentary or exercised group; both groups underwent to a myocardial infarction. All the molecular and immunohistochemical analyses on hearts of sedentary and exercised rats were performed 48 h after surgical procedure. SIRT1 and SIRT3 expression were measured and two of the pathways activated by sirtuins, p53-induced apoptosis and Forkhead boxO (FOXO)3a-induced oxidative stress, were investigated. All the experiments were performed also in presence of the SIRT inhibitor, EX527. Key findings Fourty-eight hours post myocardial infarction, exercise training induced the activation of SIRT1 and SIRT3 pathway reducing cardiomyocytes apoptosis and oxidative damage. Molecular data were confirmed by immunohistochemical evaluations. These effects are more evident in border infarcted zone than in the remote myocardium. Significance Exercise training is a non-pharmacological prevention strategy in cardiovascular diseases and the sirtuins family seems to be as novel and attractive target in cardioprotection.
- Published
- 2019
- Full Text
- View/download PDF
36. Novel quinoline compounds active in cancer cells through coupled DNA methyltransferase inhibition and degradation
- Author
-
Clemens Zwergel, Marco Tripodi, Donatella Del Bufalo, Annalisa Romanelli, Daniela Trisciuoglio, Cecilia Battistelli, Lucia Altucci, Giulia Stazi, Paola B. Arimondo, Rossella Fioravanti, Teresa De Luca, Alexandra Paulo, Dany Pechalrieu, Sergio Valente, Raffaele Strippoli, Angela Nebbioso, Federica Sarno, Eduarda Mendes, Antonello Mai, Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome] (UNIROMA), Università degli studi della Campania 'Luigi Vanvitelli' = University of the Study of Campania Luigi Vanvitelli, Universidade de Lisboa = University of Lisbon (ULISBOA), Istituto Nazionale di Malattie Infettive 'Lazzaro Spallanzani' (INMI), Department of Molecular Medicine, Institut Pasteur, Fondation Cenci Bolognetti - Istituto Pasteur Italia, Fondazione Cenci Bolognetti, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome] (UNIROMA), Pharmacochimie de la Régulation Epigénétique du Cancer (ETaC), PIERRE FABRE-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Chimie biologique épigénétique - Epigenetic Chemical Biology (EpiCBio), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), IFO - Istituto Nazionale Tumori Regina Elena [Roma] (IRE), CNR Istituto di Biologia e Patologia Molecolari [Roma] (CNR | IBPM), National Research Council of Italy | Consiglio Nazionale delle Ricerche (CNR), This work was supported by PRIN 2016 (prot. 20152TE5PK) (L.A., A.M.), Ricerca Finalizzata 2013 PE-2013-02355271 (A.M.), the Italian Association for Cancer Research AIRC-19162 (A.M.), AIRC-17217 (L.A.) and AIRC-18560 (D.D.B.), NIH (n. R01GM114306) (A.M.), VALERE: Vanvitelli per la Ricerca Program (L.A.), FP7-BLUEPRINT (282510) (L.A., A.M.), the Campania Regional Government Lotta alle Patologie Oncologiche (L.A.), iCURE (CUP B21c17000030007) (L.A.), Campania Regional Government FASE 2: IDEAL (CUP B63D18000560007) (L.A.), PlanCancer2014 (P.B.A.) and FCT, Portugal through UID/DTP/04138/2019 (A.P., E.M.) funds., Zwergel, C., Fioravanti, R., Stazi, G., Sarno, F., Battistelli, C., Romanelli, A., Nebbioso, A., Mendes, E., Paulo, A., Strippoli, R., Tripodi, M., Pechalrieu, D., Arimondo, P. B., De Luca, T., Del Bufalo, D., Trisciuoglio, D., Altucci, L., Valente, S., Mai, A., Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], Università degli studi della Campania 'Luigi Vanvitelli', Universidade de Lisboa (ULISBOA), Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome]-Institut Pasteur, Fondation Cenci Bolognetti - Istituto Pasteur Italia, Fondazione Cenci Bolognetti, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Institute of Molecular Pathology and Biology [Rome] (IPBM), and Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome]-Consiglio Nazionale delle Ricerche (CNR)
- Subjects
0301 basic medicine ,Cancer Research ,Methyltransferase ,[SDV]Life Sciences [q-bio] ,Azacitidine ,Decitabine ,DNA methyltransferase ,Apoptosis ,Medicinal chemistry ,Protein degradation ,lcsh:RC254-282 ,Article ,03 medical and health sciences ,0302 clinical medicine ,medicine ,[CHIM]Chemical Sciences ,Chemistry ,Drug discovery ,Apoptosi ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,3. Good health ,Enzyme inhibition ,030104 developmental biology ,Oncology ,Cell culture ,030220 oncology & carcinogenesis ,Cancer cell ,Cancer research ,DNMT1 ,medicine.drug - Abstract
DNA methyltransferases (DNMTs) play a relevant role in epigenetic control of cancer cell survival and proliferation. Since only two DNMT inhibitors (azacitidine and decitabine) have been approved to date for the treatment of hematological malignancies, the development of novel potent and specific inhibitors is urgent. Here we describe the design, synthesis, and biological evaluation of a new series of compounds acting at the same time as DNMTs (mainly DNMT3A) inhibitors and degraders. Tested against leukemic and solid cancer cell lines, 2a&ndash, c and 4a&ndash, c (the last only for leukemias) displayed up to submicromolar antiproliferative activities. In HCT116 cells, such compounds induced EGFP gene expression in a promoter demethylation assay, confirming their demethylating activity in cells. In the same cell line, 2b and 4c chosen as representative samples induced DNMT1 and -3A protein degradation, suggesting for these compounds a double mechanism of DNMT3A inhibition and DNMT protein degradation.
- Published
- 2020
- Full Text
- View/download PDF
37. Toward a Personalized Therapy in Soft-Tissue Sarcomas: State of the Art and Future Directions
- Author
-
Bianca Arianna Facchini, Stefano De Simone, Salvatore Tafuto, Lucia Altucci, Gaetano Facchini, Ferdinando De Vita, Liliana Montella, Elisena Franzese, Carlo Buonerba, Federica Sarno, Massimiliano Berretta, Montella, L., Altucci, L., Sarno, F., Buonerba, C., De Simone, S., Facchini, B. A., Franzese, E., Vita, F. D., Tafuto, S., Berretta, M., and Facchini, G.
- Subjects
0301 basic medicine ,Cancer Research ,sarcoma ,precision medicine ,translocation ,Review ,03 medical and health sciences ,Genetic signature ,0302 clinical medicine ,Medicine ,Personalized therapy ,genome ,RC254-282 ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Soft tissue ,personalized medicine ,medicine.disease ,Precision medicine ,030104 developmental biology ,Innovative Therapies ,Oncology ,030220 oncology & carcinogenesis ,Genome ,Personalized medicine ,Sarcoma ,Translocation ,Cancer research ,business ,Median survival - Abstract
Simple Summary Soft-tissue sarcomas encompass heterogeneous histotypes with variable clinical behavior. The cornerstone of treatment is represented by surgery when the disease is diagnosed at an early stage. However, in recurrent and metastatic stages, conventional available therapeutic options yield disappointing results. In the era of precision medicine characterized by exciting advancements in several malignancies, soft-tissue sarcoma treatment still represents an unmet need. Abstract Soft-tissue sarcomas are rare tumors characterized by pathogenetic, morphological, and clinical intrinsic variability. Median survival of patients with advanced tumors are usually chemo- and radio-resistant, and standard treatments yield low response rates and poor survival results. The identification of defined genomic alterations in sarcoma could represent the premise for targeted treatments. Summarizing, soft-tissue sarcomas can be differentiated into histotypes with reciprocal chromosomal translocations, with defined oncogenic mutations and complex karyotypes. If the latter are improbably approached with targeted treatments, many suggest that innovative therapies interfering with the identified fusion oncoproteins and altered pathways could be potentially resolutive. In most cases, the characteristic genetic signature is discouragingly defined as “undruggable”, which poses a challenge for the development of novel pharmacological approaches. In this review, a summary of genomic alterations recognized in most common soft-tissue sarcoma is reported together with current and future therapeutic opportunities.
- Published
- 2021
- Full Text
- View/download PDF
38. Gene Transactivation and Transrepression in MYC-Driven Cancers
- Author
-
Lucia Altucci, Vincenzo Carafa, Marika Scafuro, Angela Nebbioso, Lucia Capasso, Scafuro, M., Capasso, L., Carafa, V., Altucci, L., and Nebbioso, A.
- Subjects
Lymphoma ,Transcription Factor ,Carcinogenesis ,Cellular differentiation ,Regulator ,MYC-driven cancers ,Apoptosis ,Review ,MYC ,Proto-Oncogene Mas ,Epigenesis, Genetic ,lcsh:Chemistry ,Epigenome ,Transactivation ,Neoplasms ,Homeostasis ,lcsh:QH301-705.5 ,Carcinogenesi ,Kruppel-Like Transcription Factor ,Spectroscopy ,Transrepression ,Leukemia ,Stem Cells ,therapeutic target ,Cell Differentiation ,General Medicine ,Chromatin ,Computer Science Applications ,Cell biology ,Gene Expression Regulation, Neoplastic ,Cyclin-Dependent Kinase Inhibitor p27 ,Human ,Signal Transduction ,Transcriptional Activation ,therapy resistance ,MYC-driven cancer ,Kruppel-Like Transcription Factors ,Biology ,Catalysis ,Chromatin remodeling ,Proto-Oncogene Proteins c-myc ,Inorganic Chemistry ,Stem Cell ,Homeostasi ,Animals ,Humans ,Epigenetics ,Physical and Theoretical Chemistry ,Molecular Biology ,Cell Proliferation ,Animal ,Genome, Human ,Organic Chemistry ,Apoptosi ,Hematopoietic Stem Cell ,Hematopoietic Stem Cells ,lcsh:Biology (General) ,lcsh:QD1-999 ,MYC deregulation ,Neoplasm ,epigenetic modulation ,Proto-Oncogene Ma ,Transcription Factors - Abstract
MYC is a proto-oncogene regulating a large number of genes involved in a plethora of cellular functions. Its deregulation results in activation of MYC gene expression and/or an increase in MYC protein stability. MYC overexpression is a hallmark of malignant growth, inducing self-renewal of stem cells and blocking senescence and cell differentiation. This review summarizes the latest advances in our understanding of MYC-mediated molecular mechanisms responsible for its oncogenic activity. Several recent findings indicate that MYC is a regulator of cancer genome and epigenome: MYC modulates expression of target genes in a site-specific manner, by recruiting chromatin remodeling co-factors at promoter regions, and at genome-wide level, by regulating the expression of several epigenetic modifiers that alter the entire chromatin structure. We also discuss novel emerging therapeutic strategies based on both direct modulation of MYC and its epigenetic cofactors.
- Published
- 2021
- Full Text
- View/download PDF
39. Regulatory Interplay between miR-181a-5p and Estrogen Receptor Signaling Cascade in Breast Cancer
- Author
-
Rosaria Benedetti, Ugo Chianese, Emma Niméus, Tommaso De Marchi, Dante Rotili, Antonello Mai, Giulia Sgueglia, Francesco Iovino, Carmela Dell' Aversana, Lucia Altucci, Chiara Papulino, Benedetti, R, Papulino, C, Sgueglia, G, Chianese, U, De Marchi, T, Iovino, F, Rotili, D, Mai, A, Niméus, E, Dell' Aversana, C, and Altucci, L
- Subjects
0301 basic medicine ,Cancer Research ,miR-181a-5p ,Estrogen receptor ,hormone signaling ,lcsh:RC254-282 ,Article ,03 medical and health sciences ,breast cancer ,0302 clinical medicine ,Breast cancer ,microRNA ,medicine ,Epigenetics ,ERα ,endocrine therapy ,epigenetic SERD ,MiR-181a-5p ,biology ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Crosstalk (biology) ,030104 developmental biology ,Histone ,Oncology ,030220 oncology & carcinogenesis ,biology.protein ,Cancer research ,Demethylase ,Estrogen receptor alpha - Abstract
Simple Summary Despite huge efforts in breast cancer care programs, patient’s survival rates greatly vary. Differences in response to therapy still represent the major challenge for clinicians and biologists. Define new anticancer mechanisms and innovative predictors for resistance could be a valid strategy to permanently defeat breast cancer. Here we propose the epigenetic based reprogramming of breast cancer, which leverages on the crosstalk between miR-181a-5p and Estrogen Receptor α. This simultaneously approach allows to induce miR-181a-5p and reduce the receptor expression, blocking the estrogen-dependent proliferative pathway underlying breast cancer progression. Since the epigenetic approach insists on transcriptional regulation, it is mostly independent of the acquired resistance mechanisms typically induced by prolonged endocrine therapy and therefore can be used as a sensitizer, neoadjuvant, or in combination with the standard in care treatments against breast cancer. Abstract The efficacy and side effects of endocrine therapy in breast cancer (BC) depend largely on estrogen receptor alpha (ERα) expression, the specific drug administered, and treatment scheduling. Although the benefits of endocrine therapy outweigh any adverse effects in the initial stages of BC, later- or advanced-stage tumors acquire resistance to treatments. The mechanisms underlying tumor resistance to therapy are still not well understood, posing a major challenge for BC patient care. Epigenetic regulation and miRNA expression may be involved in the switch from a treatment-sensitive to a treatment-resistant state and could provide a valid therapeutic strategy for ERα negative BC. Here, a hybrid lysine-specific histone demethylase inhibitor, MC3324, displaying selective estrogen receptor down-regulator-like activities in BC, was used to highlight the interplay between epigenetic and ERα signaling. MC3324 anticancer action is mediated by microRNA (miRNA) expression regulation, indicating an innovative function for this molecule. Integrated analysis suggests a crosstalk between estrogen signaling, ERα interactors, miRNAs, and their putative targets. Specifically, miR-181a-5p expression is regulated by MC3324 and has an impact on cellular levels of ERα. A comparison of breast tumor versus healthy mammary tissues confirmed the important role of miR-181a-5p in ERα regulation and points to its putative predictive function in BC therapy.
- Published
- 2021
- Full Text
- View/download PDF
40. LncRNA SBF2-AS1 promotes hepatocellular carcinoma metastasis by regulating EMT and predicts unfavorable prognosis
- Author
-
Y-T, Zhang, B-P, Li, B, Zhang, P, Ma, Q-L, Wu, L, Ming, L-M, Xie, Franci, G, Dell'Aversana, C, Stelitano, D, Rinaldi, M, and Altucci, L
- Subjects
Male ,Carcinoma, Hepatocellular ,Epithelial-Mesenchymal Transition ,Prognosi ,Liver Neoplasms ,Hep G2 Cells ,Middle Aged ,Prognosis ,Gene Expression Regulation, Neoplastic ,Liver Neoplasm ,Cell Movement ,Humans ,Female ,Neoplasm Invasiveness ,RNA, Long Noncoding ,Human ,Cell Proliferation ,Retrospective Studies ,Signal Transduction - Abstract
Recent studies have furthered our understanding of the function of long noncoding RNAs (lncRNAs) in numerous biological processes, including cancer. The present study aimed to investigate the expression of lncRNA SBF2-AS1 (SBF2-AS1) in patients with hepatocellular carcinoma (HCC) and to investigate its effect on HCC cells.Using quantitative reverse transcription-polymerase chain reaction, we detected SBF2-AS1 expression in HCC cell lines and primary tumor tissues. The associations between SBF2-AS1 expression and the clinicopathological factors and outcome of HCC patients were statistically analyzed. MTT assay and transwell assay were performed to determine the proliferation, migration and invasion, respectively. In addition, we evaluated the activation of Mesenchymal-epithelial transition (EMT) pathway by Western blot.We found that SBF2-AS1 expression levels were significantly up-regulated in HCC tissues and cell lines compared with the corresponding noncancerous liver tissues and normal hepatic cell line. In addition, high SBF2-AS1 expression levels were correlated with vein invasion (p = 0.008) and TNM stage (p = 0.013). Furthermore, Kaplan-Meier survival analysis indicated that high expressions of SBF2-AS1 were correlated with shorter overall survival of HCC patients. Univariate and multivariate analysis identified high SBF2-AS1 expression as an unfavorable prognostic factor for overall survival. Further functional analysis demonstrated that knockdown of SBF2-AS1 significantly inhibited HCC cells proliferation, migration and invasion. Mechanistically, we found that SBF2-AS1 could promote the activation of EMT pathway, which was demonstrated by measuring the expression levels of EMT-related markers.SBF2-AS1 might be considered as a novel molecule involved in HCC development, which provides a potential therapeutic target for HCC.
- Published
- 2018
41. A genic and epigenetic combination therapy for liver cancer
- Author
-
Gianluigi Franci, Massimiliano Galdiero, Luciana Palomba, Rachele Isticato, Carlo Pedone, R. di Francia, Carla Zannella, Luigi Elio Adinolfi, Secondo Lastoria, Luca Rinaldi, Veronica Folliero, Lucia Altucci, Antonio Ascione, Giancarlo Morelli, I. De Sio, Rinaldi, L., Franci, G, Folliero, V, Palomba, L, Isticato, R, Zannella, C, di Francia, R, De Sio, I, Morelli, G, Lastoria, S, Altucci, L, Pedone, C, Ascione, A, Adinolfi, LE, Galdiero, M, Adinolfi, Le, Rinaldi, L, Gianluigi, Franci, Giuseppe, Morelli, Maria, Lastoria, and Carlo, Pedone
- Subjects
Hepatology ,Combination therapy ,business.industry ,Gastroenterology ,medicine ,Cancer research ,Epigenetics ,Liver cancer ,medicine.disease ,business - Abstract
Results: Cell cycle analysis was achieved on HepG2 cells transfected with TRAIL-GFP and pEGFP-p53 recombinant protein. Results were analysed with Cell-Quest and ModIFit software. Data shown the re-expression of selected recombinant proteins in over than 30% cells post 24 h from transfection. The transfected cells were treated post 24 h with MS-275 for other 8 h and the cells were collected. The total protein extract was analysed by Western blot and the apoptosis pathways were evaluated via caspase activation proteins. In details we detect the relative bands for caspase 8 and caspase 9 full lengths and activated form in transfected cells and post MS-275 treatment. Conclusion: Results showed the possibility to restore the expression of pro-apoptotic gene TRAIL and p53 in a liver cancer model HepG2. Moreover, the treatment with epigenetic modulators MS-275 enhanced the pro-apoptotic effect mediated by the re-expression of those silenced genes.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.